USA - Growing Incidence Rates, Coupled with Increasing Aging Population to Propel Global Anxiety Disorders Market

GIA announces the release of a comprehensive global report on the Anxiety Disorders market. The global market for anxiety disorders is forecast to reach $6 billion by the year 2017, driven by the increasing number of people suffering from anxiety disorders, coupled with the growing aging population.

Additionally, the market is expected to gain impetus due to the existence of significant unmet needs, and also derive substantial benefit from the research and development activity being undertaken for novel therapeutics.

Anxiety disorder is the most commonly occurring mental health condition, affecting individuals of all age groups. The disorder involves unwarranted amount of fear, anxiety, nervousness, dread or worry that renders an affected person tense and distracted. In the recent years, the number of people suffering from anxiety disorders increased considerably owing to the global financial crisis that resulted in rising unemployment rates and increasing stress levels.

Ever-increasing aging global population is also one of the factors responsible for the rapid increase in sales of central nervous system drugs.

Against this backdrop, there exists an ever-increasing need for developing medications that offer a faster onset of action as compared to the presently available drugs. Subsequently, the anxiety disorders market is expected to witness a transformation, with anti-psychotic drugs expected to change the future landscape of the anxiety disorder drugs market. Seroquel XR is expected to leverage first to market status, subsequent to its approval for use in generalized anxiety disorder.

Manufacturers of anti-depressants are expected to enhance their products' target patient potential, considering the higher co-morbidity between depression and anxiety.

However, pharmaceutical companies in the anxiety disorder drugs market are expected to be challenged by the need of maintaining and growing the market share due to the patent expiries of the three major drug brands, including Cymbalta, Lexapro and the extended release version of Effexor, during the period 2011-2013, thereby leading to strong competition among other classes of antidepressant drugs.

Pharmacotherapy, as well as psychotherapeutic approaches, has been established to be effective in treating Generalized Anxiety Disorder (GAD). The combination of these two approaches is expected to curtail limitations of any single approach and result in enhanced improvement in the condition. The combination is also helpful for patients not benefiting from any one of the methods. Several novel therapeutic drugs are currently under development for treating Generalized Anxiety Disorder (GAD).

These include agents that act by modifying Neurokinins, Cholecystokinin, γ-aminobutyric acid or GABA, voltage sensitive Ca2+ channels, and serotonin 5-HT1A receptors. Research efforts have strongly moved towards 5-HT1A-Receptor Agonists, following the launch of Buspirone. A promising product in pipeline is Pregabalin that helps in modulating Ca2+ channel flow in hyperexcited neurons.

The US represents the largest regional market for anxiety disorder therapeutics worldwide, as stated by the new market research report on Anxiety Disorders. Anxiety disorders are the most common form of psychological disorder in the US. About 40 million people suffer from an anxiety disorder in the US.

About 10 million Americans are believed to visit a psychiatrist for dealing with stress-related issues per annum. Anti-anxiety drugs, antidepressants and tranquilizers account for about 25% of the total prescriptions dispensed in the US per annum. About 27% of the European population suffers from brain disorders, with depression being the most prevalent health problem in several EU-Member States.

However, Asia-Pacific is forecast to register the fastest growth during the analysis period, registering a compounded annual growth rate of more than 5.0% during 2009-2017.

Major players profiled in the report include AstraZeneca Plc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Forest Laboratories, Inc., GlaxoSmithKline Plc, H. Lundbeck A/S, Mylan Inc., Neurocrine Biosciences, Inc., Pfizer Inc., Ratiopharm, Sanofi, Valeant Pharmaceuticals, Watson Laboratories, among others.

The research report titled “Anxiety Disorders: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of the anxiety disorders therapeutics markets, current market trends, key growth drivers, leading drugs in the market, overview of pipeline drugs, recent product approvals/launches, recent industry activity, and profiles of major/niche global as well as regional market participants.

The report provides annual sales estimates and projections for anxiety disorders therapeutics market for the years 2009 through 2017 for the following geographic markets - US, Europe, Asia-Pacific, and Rest of World. Also, a six-year (2003-2008) historic analysis is provided for additional perspective.

For more details about this comprehensive market research report, please visit –
http://www.strategyr.com/Anxiety_Disorders_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.